Likarda is the leading regenerative medicine company for companion animals. We are in the process of commercializing a better way to manage diabetes in dogs and cats. We do this through insulin-producing cell clusters, called the Kanslet™, that we can infuse into animals with diabetes.
With an estimated 1 in 100 dogs and cats contracting diabetes in their lifetime, nearly 1.5 million pets will suffer from diabetes at some point. Currently, the only option for treatment is twice daily insulin injections, placing enormous stress on pets and their owners. Through years of development and working with various partners, Likarda is in the process of bringing islet transplants to dogs. The microencapsulated islets (the insulin-producing cells of the body) are transplanted via injection into the belly of a diabetic dog, removing the need for twice daily insulin injections.
When ready for market, the process will allow veterinarians to offer a minimally invasive, cost-effective answer to pet owners battling the burden of diabetes in dogs and cats.
Where We Are in The Process:
Currently, we are in the clinical testing phase of the process. While we have all the trial candidates we need for this round, we may need future qualified candidates. We anticipate the treatment could be released to the market as early as Fall 2020. If you’d like to be considered for a future round of clinical trials, or to be alerted when the treatment is ready for your vet, please fill out the form below.